Live Preview
Tag didn’t load? Click here and let us know!Share this result
Previews are deleted daily. Get a permanent share link sent to your inbox:
Script
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word">
<head>
<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1" />
<meta name="format-detection" content="email=no" />
<meta name="format-detection" content="telephone=no" />
<meta name="format-detection" content="address=no" />
<meta name="x-apple-disable-message-reformatting" />
<meta name="color-scheme" content="light-dark" />
<meta name="supported-color-schemes" content="light-dark" />
<title>IBRANCE: scopri di più sul beneficio in OS associato al trattamento con CDK4/6-i nelle pazienti con età ≥65 anni con HR+/HER2- mBC nella real world</title>
<!--[if gte mso 9]>
<style type="text/css">
sup {font-size:100% !important;}
</style>
<![endif]-->
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
<o:PixelsPerInch>96</o:PixelsPerInch>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<style type="text/css">
:root {
color-scheme: light dark;
supported-color-schemes: light dark;
}
.gmail {
display: none !important;
width: 0 !important;
}
table, td {
border-collapse: collapse !important;
mso-table-lspace: 0pt;
mso-table-rspace: 0pt;
}
button {
margin: 0 !important;
padding: 0 !important;
border: 0 !important;
cursor: default !important;
font-size: 0px !important;
line-height: 0px !important;
}
td {
font-size: 0px;
line-height: 0px;
mso-text-raise: 20% !important;
}
div {
font-size: 0px;
line-height: 0px;
}
th {
font-weight: normal !important;
}
</style>
</head>
<body yahoo="fix" style="margin: 0; padding: 0; font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 1.231; -webkit-text-size-adjust: none;">
<div bgcolor="#ffffff" align="center">
<table bgcolor="#ffffff" align="center" cellpadding="0" cellspacing="0" border="0" width="100%" role="presentation" style="margin: 0 auto;">
<!--PRE-HEADER-->
<tr>
<td id="emailPreheader" style="font-family:Arial, Helvetica, sans-serif; font-size:0px; line-height:0px; color:#fffffc; mso-hide:all;"> ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ </td>
</tr>
<!--EN OF PRE-HEADER-->
<tr>
<td align="center" width="600" id="iosWrapper"><table width="600" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="font-size:0px; line-height:0px;"><img src="header.jpg" width="600" height="342" style="border:0; display:block; font-size:10px; line-height:12px; text-align: center;" alt="Ibrance palbociclib"/></td>
</tr>
<tr>
<td><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="font-size:0px; line-height:0px;" width="36"></td>
<td><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="font-family: Arial, Helvetica, sans-serif; font-size:18px; line-height:22px; color:#430098; text-align:left; font-weight: bold; padding-top: 40px;">Gentile Dottore/Dottoressa {{accFname}} {{accLname}},</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; color:#000000; text-align:left; padding-top: 25px;">Sono stati recentemente pubblicati i risultati di uno <b>studio retrospettivo di coorte</b> condotto utilizzando il <b>database</b> <i>Survey Epidemiology and End Results</i> <strong>(SEER)‑Medicare</strong><sup style="font-size: 70%; line-height: 70%; vertical-align: 60%; mso-text-raise:20%;"> 3</sup></td>
</tr>
</table></td>
<td style="font-size:0px; line-height:0px;" width="36"></td>
</tr>
</table></td>
</tr>
<tr>
<td><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="font-size:0px; line-height:0px;" width="32"></td>
<td><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td width="77" style="vertical-align: top;"><table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="20" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td width="77" height="77" valign="top" style="font-size:0px; line-height:0px;" align="center"><img src="icon1.png" width="77" height="77" style="border:0; display:block; font-size:10px; line-height:12px;" alt=""></td>
</tr>
</table></td>
<td style="vertical-align: top;"><table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="30" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td style="font-size:0px; line-height:0px;" width="20"></td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:17px; color:#000000; text-align:left;" width="10" valign="top">• </td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; color:#000000; text-align:left;"><b>OBIETTIVO:</b> valutare il <b>beneficio in OS</b> associato al trattamento con <b>CDK4/6‑i</b> nelle <b>pazienti con età ≥65 anni</b> con HR+/HER2‑ mBC del Medicare<sup style="font-size: 70%; line-height: 70%; vertical-align: 60%; mso-text-raise:20%;"> 3</sup></td>
<td style="font-size:0px; line-height:0px;" width="25"></td>
</tr>
</table></td>
</tr>
<tr>
<td width="77" style="vertical-align: top;"><table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="12" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td width="77" height="77" valign="top" style="font-size:0px; line-height:0px;" align="center"><img src="icon2.png" width="77" height="77" style="border:0; display:block; font-size:10px; line-height:12px;" alt=""></td>
</tr>
</table></td>
<td style="vertical-align: top;"><table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="22" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td style="font-size:0px; line-height:0px;" width="20"></td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:17px; color:#000000; text-align:left;" width="10" valign="top">• </td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; color:#000000; text-align:left;"><b>POPOLAZIONE INCLUSA:</b> pazienti con una <b>prima diagnosi di HR+/HER2‑ mBC</b> (per es. <b>stadio IV</b> alla prima diagnosi) dal 2015 al 2017<sup style="font-size: 70%; line-height: 70%; vertical-align: 60%; mso-text-raise:20%;"> 3</sup></td>
<td style="font-size:0px; line-height:0px;" width="25"></td>
</tr>
</table></td>
</tr>
<tr>
<td width="77" style="vertical-align: top;"><table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="12" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td width="77" height="77" valign="top" style="font-size:0px; line-height:0px;" align="center"><img src="icon3.png" width="77" height="77" style="border:0; display:block; font-size:10px; line-height:12px;" alt=""></td>
</tr>
</table></td>
<td style="vertical-align: top;"><table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="22" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td style="font-size:0px; line-height:0px;" width="20"></td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:17px; color:#000000; text-align:left;" width="10" valign="top">• </td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; color:#000000; text-align:left;"><b>RISULTATI:</b> dimostrato <b>significativo beneficio in OS</b> con <b>ET + CDK4/6‑i</b> rispetto alla sola ET, in linea con quanto osservato negli studi clinici<sup style="font-size: 70%; line-height: 70%; vertical-align: 60%; mso-text-raise:20%;"> 3</sup></td>
<td style="font-size:0px; line-height:0px;" width="25"></td>
</tr>
</table></td>
</tr>
</table></td>
</tr>
</table></td>
<td style="font-size:0px; line-height:0px;" width="36"></td>
</tr>
</table></td>
</tr>
<tr>
<td height="42" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="font-size:0px; line-height:0px;" width="36"></td>
<td><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="font-size:0px; line-height:0px;"><img src="banner.jpg" width="528" height="84" style="border:0; display:block; font-size:10px; line-height:12px; text-align: center;" alt="È importante sottolineare che in questa analisi le pazienti nel gruppo dei CDK4/6-i erano trattate in prevalenza con IBRANCE. Di fatto, questo indica che IBRANCE ha rappresentato il driver principale dei risultati osservati nello studio [3]"/></td>
</tr>
<tr>
<td height="28" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td><table width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="#82bc00">
<tr>
<td style="font-family: Arial, Helvetica, sans-serif; font-size:18px; line-height:19px; color:#ffffff; text-align:center; font-weight: bold; padding-top: 12px;"><a href="https://webfiles.pfizer.com/ibrance_ipdf_pazienti_anziani_2023" style="color: #ffffff; text-decoration: underline;" target="_blank">APPROFONDISCA QUI</a></td>
</tr>
<tr>
<td style="font-family: Arial, Helvetica, sans-serif; font-size:14px; line-height:16px; color:#ffffff; text-align:center; font-weight: bold;">i risultati dello studio di <i>real‑world</i> condotto nelle pazienti<br/>
con età ≥65 anni con HR+/HER2‑ mBC del database SEER‑Medicare</td>
</tr>
<tr>
<td style="font-family: Arial, Helvetica, sans-serif; font-size:12px; line-height:14px; color:#ffffff; text-align:center; padding-top: 15px; padding-bottom: 10px;">PP‑IBR‑ITA‑0593 Depositato presso AIFA in data 29/05/2023</td>
</tr>
</table></td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:17px; color:#000000; text-align:left; padding-top: 60px;">Cordiali saluti,</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left; padding-top: 15px;">{{userName}} <br/>
<a href="mailto:{{userEmailAddress}}" target="_self" style="color: #000000; text-decoration: none;">{{userEmailAddress}}</a></td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left; padding-top: 50px;"><b>CDK:</b> chinasi ciclina‑dipendenti; <b>CDK4/6‑i:</b> inibitori di CDK4/6; <b>ET:</b> terapia endocrina; <b>HER2‑:</b> negativo al recettore del fattore di crescita epidermico umano 2; <b>HR+:</b> positivo ai recettori ormonali; <b>mBC:</b> carcinoma mammario metastatico; <b>OS:</b> sopravvivenza globale</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left; padding-top: 24px;">Prescrivibile SSN: Classe H – RNRL: Medicinale soggetto a prescrizione medica limitativa, da rinnovare volta per volta,
vendibile al pubblico su prescrizione di centri ospedalieri o di specialisti: oncologo (RNRL).<br/>
IBRANCE 21 cpr da 75 mg: prezzo al pubblico 5.941,43 €<br/>
IBRANCE 21 cpr da 100 mg: prezzo al pubblico 5.941,43 €<br/>
IBRANCE 21 cpr da 125 mg: prezzo al pubblico 5.941,43 €<br/>
I prezzi indicati sono comprensivi delle riduzioni di cui alle det. AIFA 03.07.2006 e 27.09.2006</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#000000; font-weight: bold; text-align:center; padding-top: 12px;">Per ulteriori informazioni cliniche e sul profilo di sicurezza del medicinale fare riferimento <br/>
al <a href="https://webfiles.pfizer.com/file/rcp/ibrance-compresse" style="color: #000000; text-decoration: underline;" target="_blank">Riassunto delle Caratteristiche del Prodotto</a>.</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left; font-weight: bold; padding-top: 25px;">Bibliografia</td>
</tr>
<tr>
<td style="vertical-align: top;"><table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="10" style="font-size:0px; line-height:0px;"></td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; font-weight: bold; text-align:left;" width="10" valign="top">1. </td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left;">Ettl J, Harbeck N. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. Expert Rev Anticancer Ther. 2017;17(8):661‑668.</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; font-weight: bold; text-align:left;" width="10" valign="top">2. </td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left;">de Dueñas EM, Gavila‑Gregori J, Olmos‑Antón S, et al. Preclinical and clinical development of palbociclib and future perspectives. Clin Transl Oncol. 2018;20(9):1136‑1144.</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; font-weight: bold; text-align:left;" width="10" valign="top">3. </td>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left;">Goyal RK, Chen H, Abughosh SM, et al. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2‑ metastatic breast cancer in the United States: A SEER‑Medicare population‑based study. Cancer. 2023;129(7):1051‑1063.</td>
</tr>
</table></td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left; letter-spacing: -0.2px; padding-top: 25px;">PP‑IBR‑ITA‑0593 depositato presso AIFA in data 29/05/2023 + PP‑IBR‑ITA‑0606 depositato presso AIFA in data 05/07/2023</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:10px; color:#000000; text-align:left; letter-spacing: -0.1px; padding-top: 22px;">II materiale ed il contenuto di questa comunicazione è indirizzato esclusivamente al destinatario di questa email, ai sensi del D.Lgs. 219/2006. Tale materiale è di proprietà di Pfizer s.r.l. (e/o di terzi con i quali Pfizer ha convenuto specifiche disposizioni in merito ai limiti di utilizzo) ed è protetto dalla normativa vigente in materia di tutela del diritto d’autore. La riproduzione, la comunicazione e la messa a disposizione e la diffusione senza l’autorizzazione del titolare dei diritti è vietata e soggetta alle sanzioni previste dalla legge.</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:10px; color:#000000; text-align:left; padding-top: 5px;">Se non desidera più ricevere comunicazioni da Pfizer può contattarci all’indirizzo email <a href="mailto:gdpritaly@pfizer.com" target="_self" style="color: #000000; text-decoration: underline;">gdpritaly@pfizer.com</a>, inserendo nell’oggetto della comunicazione ‘’unsubscribe’’. Per accedere all’informativa sulla Privacy completa <a href="https://privacycenter.pfizer.com/it/italy" style="color: #000000; text-decoration: underline;" target="_blank">clicchi qui</a>.</td>
</tr>
<tr>
<td style="font-family:Arial, Helvetica, sans-serif; font-size:10px; line-height:12px; color:#000000; text-align:left; padding-top: 15px;">Cod. AIFA PP‑IBR‑ITA‑0606 ‑ Pubblicità rivolta ai medici depositata in AIFA il: 05/07/2023. <br/>
VIETATA LA DISTRIBUZIONE/ESPOSIZIONE AL PUBBLICO </td>
</tr>
<tr>
<td align="right" style="font-size:0px; line-height:0px;"><img src="logo.png" width="122" height="69" style="border:0; display:block; font-size:10px; line-height:12px; text-align: center" alt="Pfizer logo"/></td>
</tr>
</table></td>
<td style="font-size:0px; line-height:0px;" width="36"></td>
</tr>
</table></td>
</tr>
</table></td>
</tr>
</table>
</div>
<table border="0" cellpadding="0" cellspacing="0">
<tr>
<td class="no-mobile" style="min-width:500px;">
<div class="gmail" style="white-space:nowrap; font:15px courier; line-height:0;"> </div></td>
</tr>
</table>
</body>
</html>Landing Page
This ad does not have a landing page available
Network Timeline
Performance Summary
13
Requests
1
Domains
5KB
Transfer Size
24KB
Content Size
109.0ms
Dom Content Loaded
302.0ms
First Paint
223.0ms
Load Time
Domain Breakdown
Transfer Size (bytes)
Loading...
Content Size (bytes)
Loading...
Header Size (bytes)
Loading...
Requests
Loading...
Timings (ms)
Loading...
Total Time
Loading...
Content Breakdown
Transfer Size (bytes)
Loading...
Content Size (bytes)
Loading...
Header Size (bytes)
Loading...
Requests
Loading...